Streptozotocin. 1982-2022: forty years from the fda ’s approval to treat pancreatic neuroendocrine tumors

On May 1982, the US Food and Drug Administration (FDA) approved the use of
streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year
marks forty years since that landmark date. This review of streptozotocin to treat
panNETs is intended to commemorate this anniversary. A historical perspective of
chemical structure, pharmacokinetics, and mechanism of action of streptozotocin is
followed by data from prospective and retrospective clinical studies. The last section of
the review addresses the latest aspects and takes note of the prospects that lie ahead
on the future horizon of the use of streptozotocin to treat panNETs, including ongoing
clinical trials.

Source: Neuroendocrinology - May 10, 2022 Category: Endocrinology Source Type: research